Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04505397 · ClinicalTrials.gov registry record · Phase 1
Single-Dose Escalation Study Followed by a Multiple-Dose Escalation Study of SKL24741 in Healthy Subjects
A Phase 1 study, sponsored by SK Life Science.
- Completed
- Registry status
- Phase 1
- Development phase
- 111
- Enrollment target
NCT04505397 is a Phase 1 study that has completed, run by SK Life Science. The registered enrollment target is 111 participants.
The verdict
NCT04505397, a Phase 1 study, has completed, sponsored by SK Life Science.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 111 participants
- Enrollment target
Study Summary
This study evaluates SKL24741 safety and tolerability in healthy subjects. Subjects will be randomized to receive oral doses of SKL24741 or placebo. This is a two-part, double-blinded, randomized study of SKL24741.
Interventions
- DRUG Placebo
- DRUG SKL24741
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 111 participants |
| Start Date | 2020-02-13 |
| Est. Completion | 2022-10-27 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04505397
The ClinicalTrials.gov registry entry for NCT04505397 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 111 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is SK Life Science, which has 25 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04505397 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04505397 about?
NCT04505397 is a clinical study titled "Single-Dose Escalation Study Followed by a Multiple-Dose Escalation Study of SKL24741 in Healthy Subjects". This study evaluates SKL24741 safety and tolerability in healthy subjects. Subjects will be randomized to receive oral doses of SKL24741 or placebo. This is a two-part, double-blinded, randomized study of SKL24741.
What is the current status of trial NCT04505397?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 111 participants. The study started on 2020-02-13. Estimated completion is 2022-10-27.
What interventions are being tested in trial NCT04505397?
The interventions under investigation include: Placebo (DRUG), SKL24741 (DRUG).
Who is sponsoring clinical trial NCT04505397?
This trial is sponsored by SK Life Science, which has 25 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.